| A comparison of dorzolamide/timolol-fixed combination versus bimatoprost in patients with open-angle glaucoma who are poorly controlled on latanoprost. | |
| | |
MedLine Citation:
|
PMID: 18627340 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: The aim of this study was to evaluate the intraocular pressure (IOP) efficacy and safety of dorzolamide/timolol in fixed combination (DTFC) versus bimatoprost in open-angle glaucoma (OAG) patients poorly controlled (> or =21 mmHg) on latanoprost. METHODS: This was a prospective, double-masked, randomized, controlled, cross-over evaluation. After a 6-week wash-out period, the patients then returned for baseline diurnal curve testing every 2 h (8 AM to 8 PM). Patients with an IOP of 22-29 mmHg inclusive at 8 AMwere randomized to either bimatoprost dosed each evening or DTFC twice-daily. Patients returned in 8 weeks for the Period 1 diurnal curve and were switched to the opposite treatment. Patients again returned in 8 weeks for the Period 2 diurnal curve. RESULTS: Of the 29 patients, mean untreated baseline IOP (visit 2) was 24.6 +/- 2.6 mmHg and treatment mean IOP was statistically lower with bimatoprost 17.6 +/- 2.0 mmHg than for DTFC 18.8 +/- 2.5 mmHg (P = 0.03), as was the IOP range (P = 0.02) and IOP peak (P = 0.003). No significant differences were found between DTFC and bimatoprost at individual time points after a modified Bonferroni correction (>0.02). DTFC demonstrated a greater incidence of stinging or burning (n = 12) than bimatoprost (n = 0; P = < 0.0001). CONCLUSIONS: This study suggests that OAG patients generally can obtain similar IOP control at individual time points (when a Bonferroni correction is considered) by switching to either DTFC or bimatoprost, but overall diurnal control is statistically better with bimatoprost. |
| | |
Authors:
|
Elizabeth D Sharpe; Robert D Williams; Jeanette A Stewart; Lindsay A Nelson; William C Stewart |
Publication Detail:
|
Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial |
Journal Detail:
|
Title: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics Volume: 24 ISSN: 1557-7732 ISO Abbreviation: J Ocul Pharmacol Ther Publication Date: 2008 Aug |
Date Detail:
|
Created Date: 2008-07-30 Completed Date: 2009-01-05 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9511091 Medline TA: J Ocul Pharmacol Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 408-13 Citation Subset: IM |
Affiliation:
|
Glaucoma Consultants & Center for Eye Research, Mount Pleasant, SC, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over Amides / administration & dosage* Cloprostenol / administration & dosage, analogs & derivatives* Cross-Over Studies Double-Blind Method Drug Administration Schedule Drug Combinations Female Glaucoma, Open-Angle / drug therapy*, pathology Humans Male Middle Aged Prospective Studies Prostaglandins F, Synthetic / administration & dosage* Sulfonamides / administration & dosage* Thiophenes / administration & dosage* Timolol / administration & dosage* |
| Chemical | |
Reg. No./Substance:
|
0/Amides; 0/Drug Combinations; 0/Prostaglandins F, Synthetic; 0/Sulfonamides; 0/Thiophenes; 0/bimatoprost; 130209-82-4/latanoprost; 130693-82-2/dorzolamide; 26839-75-8/Timolol; 40665-92-7/Cloprostenol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Intravitreal bevacizumab treatment for refractory diabetic macular edema.
Next Document: Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7.